These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. Romanelli G, Cravarezza P, Pozzi A, Franchino L, Ravizzola G, Zulli R, Donati P, Prometti P, Grassi V. J Chemother; 2002 Dec; 14(6):609-17. PubMed ID: 12583553 [Abstract] [Full Text] [Related]
26. Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime. Ho A, Leung R, Lai CK, Chan TH, Chan CH. Respiration; 1997 Dec; 64(3):224-8. PubMed ID: 9154675 [Abstract] [Full Text] [Related]
31. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group. Brismar B, Akerlund JE, Sjöstedt S, Johansson C, Törnqvist A, Bäckstrand B, Bång H, Andåker L, Gustafsson PO, Darle N, Angerås M, Falk A, Tunevall G, Kasholm-Tengve B, Skau T, Nyström PO, Gasslander T, Hagelbäck A, Olsson-Liljequist B, Eklund AE, Nord CE. Scand J Infect Dis; 1996 Dec; 28(5):507-12. PubMed ID: 8953683 [Abstract] [Full Text] [Related]
35. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group. Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482 [Abstract] [Full Text] [Related]
36. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Cherif H, Björkholm M, Engervall P, Johansson P, Ljungman P, Hast R, Kalin M. Scand J Infect Dis; 2004 May 15; 36(8):593-600. PubMed ID: 15370671 [Abstract] [Full Text] [Related]
38. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, Drusano GL, Bertino JS. Diagn Microbiol Infect Dis; 2010 Nov 15; 68(3):251-8. PubMed ID: 20851549 [Abstract] [Full Text] [Related]
39. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O. J Antimicrob Chemother; 2007 Jul 15; 60(1):112-20. PubMed ID: 17537866 [Abstract] [Full Text] [Related]
40. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. Zanetti G, Harbarth SJ, Trampuz A, Ganeo M, Mosimann F, Chautemps R, Morel P, Lew D, Zimmerli W, Lange J, Glauser M. Int J Antimicrob Agents; 1999 Feb 15; 11(2):107-13. PubMed ID: 10221413 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]